Friday, September 29, 2023

China’s Economic Woes Are Impacting Small Businesses

Getty Images

China, a critical cog in the global supply chain, is in an economic jam–and that’s a problem for business owners who rely on the manufacturing superpower. Rewind to 2020: Labor shortages, production delays, increased demand, and other issues led to global supply chain disruptions, and the continued lockdowns in China worsened those woes.

One Inc. 5000 business owner, Matthew Borjes, 47, founder of the Lexington, South Carolina-based telehealth and mobile computing solution company Space Saving Solutions, saw lead times for wire shelving and baskets balloon from weeks to months and prices increase 50 to 80 percent within the first 90 to 120 days.

Today, Borjes says most of those prices have yet to come down. And rather than rebound after lockdown restrictions, China continues to face a slew of economic challenges that put pressure on U.S. business owners, including higher wages for factory workers, an ongoing tariff war with the U.S., and record-high youth unemployment, to name a few. Recently, President Biden called China a “ticking time bomb.”

But as this time bomb ticks, Inc. spoke with experts and business owners about dealing with these emerging supply chain obstacles…Continue reading

Source: China’s Economic Woes Are Impacting Small Businesses | Inc.com

#balloon #baskets #bomb #business #china #computing #economy #global #issues #labor #lockdown #production #shortage #small #solutions #supplychain #tariff #unemployment #wages #woes

 

Critics:

Several Western academics and institutions have supported the claim that China’s economy is likely to be underestimated. A paper by the US-based National Bureau of Economic Research claimed that China’s economic growth may be higher than what is reported by official statistics. An article by Hunter Clarka, Maxim Pinkovskiya and Xavier Sala-i-Martin published by the Elsevier Science Direct in 2018 employs an innovative method of satellite-recorded nighttime lights, which the authors claim to be a best-unbiased predictor of the economic growth in Chinese cities.

The results suggest that the Chinese economic growth rate is higher than the official reported data. The Li Keqiang index is an alternative measurement of Chinese economic performance that uses three variables Li preferred.Satellite measurements of light pollution are used by some analysts to model Chinese economic growth and suggest growth rate numbers in Chinese official data are more reliable, though are likely to be smoothed.

According to an article by the Federal Reserve Bank of St. Louis, China’s official statistics are of a high quality compared to other developing, middle-income and low-income countries. In 2016, China was at the 83rd percentile of middle and low-income countries, up from the 38th percentile in 2004. A study by the Federal Reserve Bank of San Francisco found that China’s official GDP statistics are “significantly and positively correlated” with externally verifiable measures of economic activity such as import and export data from China’s trade partners, suggesting that China’s economic growth was no slower than the official figures indicated.

The study by Daniel Rosen and Beibei Bao, published by the Center for Strategic and International Studies in 2015, showed that GDP in 2008 was actually 13–16 percent bigger than the official data, while 2013 GDP was accurately at $10.5 trillion rather than the official figure at $9.5 trillion. According to a research conducted by Arvind Subramanian, a former economist at the International Money Fund (IMF) and a senior fellow at the Peterson Institute for International Economics.

The size of the Chinese economy by Purchasing Power Parity in 2010 was about $14.8 trillion rather than an official estimate at $10.1 trillion by IMF, meaning that China’s GDP was underestimated by 47 percent. Chinese investment has always been highly cyclical. Ever since the 1958 Great Leap Forward, growth in fixed capital formation has typically peaked about every five years. Peaks occurred in 1978, 1984, 1988, 1993, 2003 and 2009. The corresponding troughs were in 1981, 1986, 1989, 1997 and 2005.

In China, the majority of investment is carried out by entities that are at least partially state-owned. Most of these are under the control of local governments. Thus, booms are primarily the result of perverse incentives at the local-government level. Unlike entrepreneurs in a free-enterprise economy, Chinese local officials are motivated primarily by political considerations. As their performance evaluations are based, to a large extent, on GDP growth within their jurisdictions, they have a strong incentive to promote large-scale investment projects.

A typical cycle begins with a relaxation of central government credit and industrial policy. This allows local governments to push investment aggressively, both through state-sector entities they control directly and by offering investment-promotion incentives to private investors and enterprises outside their jurisdictions. The resulting boom puts upward pressure on prices and may also result in shortages of key inputs such as coal and electricity (as was the case in 2003).

Once inflation has risen to a level at which it begins to threaten social stability, the central government will intervene by tightening enforcement of industrial and credit policy. Projects that went ahead without required approvals will be halted. Bank lending to particular types of investors will be restricted. Credit then becomes tight and investment growth begins to decline.

China has the world’s largest total banking sector assets of around $45.838 trillion (309.41 trillion CNY) with $42.063 trillion in total deposits and other liabilities. Most of China’s financial institutions are state-owned and governed. The chief instruments of financial and fiscal control are the People’s Bank of China (PBC) and the Ministry of Finance, both under the authority of the State Council. The People’s Bank of China replaced the Central Bank of China in 1950 and gradually took over private banks. It fulfills many of the functions of other central and commercial banks.

It issues the currency, controls circulation, and plays an important role in disbursing budgetary expenditures. Additionally, it administers the accounts, payments, and receipts of government organizations and other bodies, which enables it to exert thorough supervision over their financial and general performances in consideration of the government’s economic plans. The PBC is also responsible for international trade and other overseas transactions. Remittances by overseas Chinese are managed by the Bank of China (BOC), which has a number of branch offices in several countries.

Other financial institutions that are crucial, include the China Development Bank (CDB), which funds economic development and directs foreign investment; the Agricultural Bank of China (ABC), which provides for the agricultural sector; the China Construction Bank (CCB), which is responsible for capitalizing a portion of overall investment and for providing capital funds for certain industrial and construction enterprises; and the Industrial and Commercial Bank of China (ICBC), which conducts ordinary commercial transactions and acts as a savings bank for the public.

China initiated the founding of the Asian Infrastructure Investment Bank in 2015 and the Silk Road Fund in 2014, an investment fund of the Chinese government to foster increased investment and provide financial supports in countries along the One Belt, One Road. China’s economic reforms greatly increased the economic role of the banking system. In theory any enterprises or individuals can go to the banks to obtain loans outside the state plan, in practice, 75% of state bank loans go to State Owned Enterprises.

(SOEs) Even though nearly all investment capital was previously provided on a grant basis according to the state plan, policy has since the start of the reform shifted to a loan basis through the various state-directed financial institutions. It is estimated that, as of 2011, 14 trillion Yuan in loans was outstanding to local governments. Much of that total is believed by outside observers to be nonperforming. Increasing amounts of funds are made available through the banks for economic and commercial purposes. Foreign sources of capital have also increased.

China has received loans from the World Bank and several United Nations programs, as well as from countries (particularly Japan) and, to a lesser extent, commercial banks. Hong Kong has been a major conduit of this investment, as well as a source itself. On 23 February 2012, the PBC evinced its inclination to liberalize its capital markets when it circulated a telling ten-year timetable. Following on the heels of this development, Shenzhen banks were able to launch cross-border yuan remittances for individuals, a significant shift in the PBC’s capital control strictures since Chinese nationals had been previously barred from transferring their yuan to overseas account.

China has four of the world’s top ten most competitive financial centers (Shanghai, Hong Kong, Beijing, and Shenzhen), more than any other country. China has three of the world’s ten largest stock exchanges (Shanghai, Hong Kong and Shenzhen), both by market capitalization and by trade volume. As of 12 October 2020, the total market capitalization of mainland Chinese stock markets, consisting of the Shanghai Stock Exchange and Shenzhen Stock Exchange, topped US$10 trillion, excluding the Hong Kong Stock Exchange, with about US$5.9 trillion.

As of the end of June 2020, foreign investors had bought a total of US$440 billion in Chinese stocks, representing about 2.9% of the total value, and indicating that foreign investors scooped up a total of US$156.6 billion in the stocks just in the first half of 2020.The total value of China’s bond market topped US$15.4 trillion, ranked above that of Japan and the U.K., and second only to that of the U.S. with US$40 trillion, as of the beginning of September 2020. As of the end of September 2020, foreign holdings of Chinese bonds reached US$388 billion, or 2.5%, of the total value, notwithstanding an increase by 44.66% year on year….

Should Your Benefits Plan Cover Weight-Loss Drugs Like Ozempic?

Getty Images

While many employer plans cover the weight-loss drug Ozempic as a diabetes treatment, only 22 percent of U.S. employers cover any kind of prescription drugs for weight loss, according to a survey from the International Foundation of Employee Benefit Plans, a nonprofit membership organization that provides information for those working in the employee benefits industry.That could change soon.

On August 9, 2023, Wegovy drugmaker Novo Nordisk reported the results of a new study that showed once-weekly Wegovy injections cut the likelihood of serious cardiac events such as heart attacks, strokes, and cardiovascular deaths by nearly 20 percent–and analysts say a proven heart-health benefit beyond weight loss could increase pressure on more U.S. employers and insurers to pay for Wegovy and similar weight-loss drugs.

“The results [of the study] could improve the willingness to pay for obesity drugs and provide a higher incentive to treat obesity at an earlier stage,” Henrik Hallengreen Laustsen, an analyst at Jyske Bank, told Reuters. Given that more than 70 percent of adults in the U.S. are considered overweight or obese, according to the Centers for Disease Control and Prevention, there’s a great need for glucagon-like peptide-1 (GLP-1) drugs that suppress food cravings….Continue reading

By : Brit Morse

Source: Should Your Benefits Plan Cover Weight-Loss Drugs Like Ozempic? | Inc.com

#attacks #benefits #cardiac #cardiovascular #drugs #employer #industry #information #injections #Insurance #ozempic #plan #prescription #results #strokes #treatment #weightloss

 

Critics:

Some patients find that diet and exercise is not a viable option; for these patients, anti-obesity medications can be a last resort. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years.

Glucagon-like peptide-1 (GLP-1) are peptide incretin hormones involved in blood sugar control. In 2021, one review concluded that “Currently, gut peptide analogues such as semaglutide […] and […] tirzepatide are the furthest advanced in clinical development”. In 2022, a further review found that these two peptides are “the most promising candidates for the upcoming battle in the anti-obesity market”.

An article in The New York Times notes the high costs for semaglutide and potentially tirzepatide, suggesting that many people “who could most benefit from weight loss may be unable to afford such expensive drugs”. Semaglutide (Ozempic) is a GLP-1 analogue, administered once weekly. It is more effective than exenatide. In June 2021, the US Food and Drug Administration (FDA) approved semaglutide injection sold under the brand name Wegovy for long-term weight management in adults.

Wegovy was approved for medical use (“used together with diet and physical activity”) in the European Union in January 2022. A phase III clinical trial indicated that tirzepatide could be used for substantial weight loss. Specifically, phase-3 clinical trials found that after 71 weeks patients had lost 16% of their starting body weight on average. On 13 May 2022, it was approved under the name Mounjaro for type-2 diabetes (though not specifically for weight loss) .

Exenatide (Byetta) is a long-acting analogue of the hormone GLP-1, which the intestines secrete in response to the presence of food. Among other effects, GLP-1 delays stomach emptying and promotes a feeling of fullness after eating. Some people with obesity are deficient in GLP-1, and dieting reduces GLP-1 further. Byetta is currently available as a treatment for Diabetes mellitus type 2. Some, but not all, patients find that they lose substantial weight when taking Byetta.

Drawbacks of Byetta include that it must be injected subcutaneously twice daily, and that it causes severe nausea in some patients, especially when therapy is initiated. As of 2015, Byetta was recommended only for patients with Type 2 Diabetes. Liraglutide (Saxenda) is another GLP-1 analogue for daily administration, approved 2014. Orforglipron is a non-peptide GLP-1 agonist of potential interest because it can be taken orally and is chemically simpler and thus potentially cheaper than peptides such as semaglutide.

Orlistat (Xenical) reduces intestinal fat absorption by inhibiting the enzyme pancreatic lipase. Frequent oily bowel movements steatorrhea is a possible side effect of using Orlistat. But if fat in the diet is reduced, symptoms often improve. Originally available only by prescription, it was approved by the FDA for over-the-counter sale in February 2007. On 26 May 2010, the U.S. Food and Drug Administration (FDA) has approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been reported rarely with the use of this medication.

Of the 40 million users of orlistat worldwide, 13 cases of severe liver damage have been reported. Cetilistat is a medication designed to treat obesity. It acts in the same way as the older medication orlistat by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. A 2010 phase 2 trial found cetilistat significantly reduced weight and was better tolerated than orlistat. It has not been approved in the US.

The combination of phentermine and topiramate, brand name Qsymia (formerly Qnexa) was approved by the U.S. FDA on 17 July 2012, as an obesity treatment complementary to a diet and exercise regimen. In October 2012, the European Medicines Agency, by contrast, rejected the combination (Qsiva) as a treatment for obesity, citing concerns about long-term effects on the heart and blood vessels, mental health and cognitive side-effects.

Naltrexone/bupropion is a combination medication used for weight loss in those that have either obesity or overweight with some weight-related illnesses. It combines low doses of bupropion and naltrexone. Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight. In September 2014, a sustained release formulation of the medication was approved for marketing in the United States under the brand name Contrave.

The combination was approved for use in the European Union in March 2015, under the brand name Mysimba. Gelesis100 (sold under the brand name “Plenity”) is an oral superabsorbent hydrogel used for weight loss in the treatment of obesity and overweight. As Gelesis100 absorbs water, it expands in the stomach and small bowel, which may result in satiety. Gelesis100 was approved in April 2019 by the US Food and Drug Administration as a medical device.

In 2022, the American Gastroenterology Association recommended the use of Gelesis100 be limited to clinical trials due to limited evidence. Lorcaserin (Belviq) was approved 28 June 2012 for obesity with other co-morbidities. The average weight loss by study participants was modest,[ but the most common side effects of the medication are considered benign. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite.

This drug has now been withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. Sibutramine (Meridia), which acts in the brain to inhibit deactivation of the neurotransmitters, thereby decreasing appetite was approved in 1997 and withdrawn from the United States and Canadian markets in October 2010 due to cardiovascular concerns. As late as 2004, some held that Meridia was a harmless medication for fighting obesity.

Tthe US District Court of the Northern District of Ohio rejected 113 cases complaining about the negative effects of the medication, stating that the clients lacked supporting facts and that the representatives involved were not qualified enough. In October Sibutramine was withdrawn from the market for cardiovascular side effects like stroke or heart attack, sometimes fatal, in the United States, the UK, the EU, Australia, Canada, Hong Kong and Colombia.

Rimonabant (also known as SR141716; trade names Acomplia and Zimulti)was an anorectic antiobesity medication that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. It works via a specific blockade of the endocannabinoid system. It has been developed from the knowledge that cannabis smokers often experience hunger, which is often referred to as “the munchies”.

Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first medication approved in that class. Dietary supplements, foodstuffs, or programs for weight loss are heavily promoted through advertisements in print, on television, and on the internet. The US Food and Drug Administration recommends caution with use of these products, since many of the claims of safety and effectiveness are unsubstantiated, and many of the studies purporting to demonstrate their effectiveness are funded by the manufactures and suffer a high degree of bias.

Individuals with anorexia nervosa or bulimia nervosa, and some athletes, try to control body weight with diet pills, laxatives, or diuretic medications, although the latter two generally have no impact on body fat and only cause short-lived weight-loss through dehydration. Both diuretics and laxatives can cause electrolyte abnormalities which may cause cognitive, heart, and muscle problems, and can be fatal.

Canadian clinical practice 2006 guidelines state that there is insufficient evidence to recommend in favor of or against using herbal medicine, dietary supplements or homeopathy against obesity. Some botanical supplements include high dosages of compounds found in plants with stimulant effects including yohimbine and higenamine.

How AI Is Revolutionizing Health Care

Photo:
   Getty

The market value of AI in the health care industry is predicted to reach $6.6 billion by 2021. Artificial intelligence is increasingly growing in popularity throughout various industries. Most of us associate AI with things like robots, Alexa and self-driving cars. But AI is a lot more than that. AI experts see it as a revolutionary technology that could benefit many industries.

The impact of AI in the health care sector is genuinely life-changing. It is driving innovations in clinical operations, drug development, surgery and data management. AI technology is also rapidly finding its way into hospitals.AI applications are centered on three main investment areas: digitization, engagement and diagnostics.

Looking at some examples of artificial intelligence in health care, it is clear that there are exciting breakthroughs in incorporating AI in medical services. Let’s explore some of the amazing applications of AI that are revolutionizing health care….Continue reading….

By: Terence Mills

Source: How AI Is Revolutionizing Health Care

#artificialintelligencetechnology #artificialintelegence #healthcare #HealthcareNews #HealthcareInnovation

 

Critics:

The healthcare industry incorporates several sectors that are dedicated to providing health care services and products. As a basic framework for defining the sector, the United Nations’ International Standard Industrial Classification categorizes health care as generally consisting of hospital activities, medical and dental practice activities, and “other human health activities.” The last class involves activities of, or under the supervision of, nurses, midwives, physiotherapists, scientific or diagnostic laboratories, pathology clinics, residential health facilities, patient advocates or other allied health professions.

In addition, according to industry and market classifications, such as the Global Industry Classification Standard and the Industry Classification Benchmark, health care includes many categories of medical equipment, instruments and services including biotechnology, diagnostic laboratories and substances, drug manufacturing and delivery. For example, pharmaceuticals and other medical devices are the leading high technology exports of Europe and the United States.The United States dominates the biopharmaceutical field, accounting for three-quarters of the world’s biotechnology revenues.

The quantity and quality of many health care interventions are improved through the results of science, such as advanced through the medical model of health which focuses on the eradication of illness through diagnosis and effective treatment. Many important advances have been made through health research, biomedical research and pharmaceutical research, which form the basis for evidence-based medicine and evidence-based practice in health care delivery. Health care research frequently engages directly with patients, and as such issues for whom to engage and how to engage with them become important to consider when seeking to actively include them in studies. While single best practice does not exist, the results of a systematic review on patient engagement suggest that research methods for patient selection need to account for both patient availability and willingness to engage.

Health services research can lead to greater efficiency and equitable delivery of health care interventions, as advanced through the social model of health and disability, which emphasizes the societal changes that can be made to make populations healthier. Results from health services research often form the basis of evidence-based policy in health care systems. Health services research is also aided by initiatives in the field of artificial intelligence for the development of systems of health assessment that are clinically useful, timely, sensitive to change, culturally sensitive, low-burden, low-cost, built into standard procedures, and involve the patient.

Health information technology (HIT) is “the application of information processing involving both computer hardware and software that deals with the storage, retrieval, sharing, and use of health care information, data, and knowledge for communication and decision making.”


5 Signs You’re Actually Pretty Good With Money

Getty Images

Most of us strive and struggle to reach our goals. What we often forget is that accomplishing them is only half the battle. You also have to feel like you’ve accomplished them. And these two steps can be further apart than you might imagine. Couples therapists caution that we are often overly focused on the negative in relationships, which means we underestimate the strength of our bonds.

Professors warn that many highly successful professionals make themselves miserable by always chasing one more accolade. And one author went viral when she coined the term “productivity dysphoria” to describe the yawning gap between how much she gets done and how satisfied she feels with her output. In short, our actual achievements and our sense of our accomplishment often don’t line up.

And according to one finance professor, that’s as true for our finances as it is for relationships, productivity, and success. You’d think it would be relatively easy to gauge how well you’re doing financially. Bank balances and credit card statements offer clear and objective measurements, after all. But when it comes to money, we start from wildly different places and have wildly different goals. Your bank account is more of a reflection of luck and circumstances than your level of financial literacy….Continue reading..

You May Like To Read : Single-Pay Payday Loans Online

Source: 5 Signs You’re Actually Pretty Good With Money | Inc.com

#money #actual #investment #tips #business #exchange

Related contents:

Webify Sending Personalized Emails To The Potential Business Clients

Webify  is an innovative website building platform designed to empower individuals and businesses of all sizes to create professional and vi...